Breaking Down Zhejiang Garden Bio-chemical High-tech Co., Ltd. Financial Health: Key Insights for Investors

Peeling back the numbers behind Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) reveals a company with compelling scale and liquidity-2024 revenue reached approximately CNY 1.24 billion (up 13.58% year-on-year) with TTM revenue per share of CNY 2.29 and gross profit of CNY 716.37 million (gross margin 56.01%), while operational efficiency shows through a TTM operating margin of 33.40% and net profit margin of 25.35% driven by a 2024 net profit attributable to shareholders of CNY 309 million (up 60.76%); investors will want to weigh this against capital structure metrics-total debt of CNY 1.78 billion versus total equity of CNY 3.43 billion (debt/equity 51.99%) and cash and equivalents of CNY 1.54 billion-alongside cash generation (TTM operating cash flow CNY 499.39 million), solid liquidity (current ratio 2.14), valuation multiples (trailing P/E 27.45, forward P/E 18.64, P/S 6.62, P/B 2.45, EV/EBITDA 15.38) and market signals (market cap CNY 8.21 billion, beta 0.51), while growth levers include ~15% share of the global vitamin E market, a nutraceutical market projected at USD 650 billion by 2025 and segment-level revenue gains (vitamin E-driven nutraceutical revenue +20% YoY as of Q3 2023); read on to unpack how these figures translate into actionable insights for investors.

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) Revenue Analysis

Zhejiang Garden Bio-chemical High-tech Co., Ltd. delivered robust top-line performance in 2024 with notable margins and operational metrics that underline its profitability and efficiency.

• 2024 revenue: CNY 1.24 billion (up 13.58% year-over-year)
• Revenue per share (TTM): CNY 2.29
• Quarterly revenue growth: -1.20%
• Revenue per employee: ~CNY 1.22 million (1,021 employees)

• High gross margin (56.01%) suggests strong product mix or pricing power in core biochemical products.
• Operating margin (33.40%) indicates efficient cost control and scalable operations.
• Net margin (25.35%) reflects solid bottom-line conversion after operating and non-operating items.
• Negative quarterly revenue growth (-1.20%) signals short-term volatility despite healthy annual growth.

For further context on the company's background and strategic positioning, see: Zhejiang Garden Bio-chemical High-tech Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Profitability Metrics

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) delivered a markedly stronger profitability profile in the latest reported period, driven by higher net income, solid margins and healthy cash generation. Key headline figures for the trailing twelve months (TTM) and 2024 are summarized below.

• Net profit attributable to shareholders (2024): CNY 309 million, up 60.76% year-over-year.
• Return on equity (TTM): 9.90% - indicating effective deployment of shareholder capital.
• Return on assets (TTM): 3.90% - reflecting efficient use of asset base.
• Earnings per share (TTM): CNY 0.52; quarterly EPS growth: 5.50% YoY.
• Operating cash flow (TTM): CNY 499.39 million - strong cash conversion from operations.
• Profit margin: 24.31%; Operating margin: 33.70% - robust profitability at both net and operating levels.

The following table consolidates the core profitability metrics for quick comparison and reference:

For additional context on shareholders, ownership trends and investor composition that complement these profitability signals, see: Exploring Zhejiang Garden Bio-chemical High-tech Co., Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Debt vs. Equity Structure

• Total debt to equity ratio: 51.99% - moderate leverage consistent with industry peers pursuing both stability and expansion.
• Total debt: CNY 1.78 billion - the absolute debt load requiring servicing and maturity management.
• Total equity: CNY 3.43 billion - shareholders' claim providing a buffer versus liabilities.
• Cash and equivalents: CNY 1.54 billion - a meaningful liquidity cushion to cover near-term obligations and capex needs.
• Book value per share: CNY 6.29 - a snapshot of net asset value on a per-share basis.
• Enterprise value / EBITDA: 15.38 - valuation multiple indicating how the market prices the company relative to operational earnings.

• Liquidity profile: With CNY 1.54 billion in cash and equivalents versus CNY 1.78 billion total debt, short-term coverage appears adequate though maturity breakdown and working capital needs should be reviewed.
• Leverage sensitivity: A 51.99% debt/equity ratio leaves room for incremental borrowing but suggests prudence if EBITDA weakens, given EV/EBITDA of 15.38 that ties market valuation to earnings performance.
• Shareholder capitalization: Book value per share of CNY 6.29 helps contextualize market price against tangible net assets.

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Liquidity and Solvency

• Current ratio: 2.14 - indicates the company can cover short-term liabilities more than twice over with short-term assets.
• Quick ratio: not specified - the available current ratio suggests adequate near-term liquidity, though the exact quick ratio would clarify inventory dependence.
• Operating cash flow (TTM): CNY 499.39 million - positive and sizable operating cash generation supporting recurring obligations.
• Cash & equivalents: CNY 1.54 billion - a significant liquidity buffer for working capital and unexpected needs.
• Total debt: CNY 1.78 billion versus total equity: CNY 3.43 billion - implying a debt-to-equity ratio around 0.52, reflecting a balanced capital structure.
• Enterprise value / EBITDA: 15.38 - valuation metric showing the market's pricing relative to operating earnings before non-cash items and financing costs.

• Implications for creditors and investors: the strong cash balance and positive operating cash flow reduce short-term default risk, while the moderate leverage level provides growth financing capacity without excessive financial strain.
• Key monitoring items: changes in operating cash flow trends, shifts in cash reserves, maturity schedule of the CNY 1.78 billion debt, and movements in EV/EBITDA relative to industry peers.

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Valuation Analysis

• Trailing P/E: 27.45 - reflects recent earnings multiple paid by the market.
• Forward P/E: 18.64 - suggests earnings growth expectations are priced in.
• P/S: 6.62 - indicates how the market values each yuan of revenue.
• P/B: 2.45 - shows market valuation relative to net assets.
• EV/Revenue: 6.75 and EV/EBITDA: 15.38 - useful for comparing enterprise valuation to sales and operating profitability.
• Market Cap (as of 2025-07-01): CNY 8.21 billion.
• Beta: 0.51 - lower volatility than the market, implying defensive characteristics.

• Relative valuation context: the gap between trailing and forward P/E (27.45 vs. 18.64) implies anticipated earnings improvement or recent earnings weakness; EV/EBITDA at 15.38 places the company in a mid-to-high valuation band relative to typical industrial/chemical peers.
• Balance-sheet lens: P/B of 2.45 suggests investors pay a premium to net assets, consistent with growth or intellectual property value embedded in the business.
• Risk/volatility lens: beta of 0.51 signals lower sensitivity to market swings, which can be attractive for risk-averse investors seeking exposure to specialty chemicals/biochemicals.

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Risk Factors

• Leverage: debt to equity ratio at 51.99% (Total debt CNY 1.78 billion vs. Total equity CNY 3.43 billion) - signals moderate financial leverage that could amplify stress under adverse operating conditions.
• Revenue trend: quarterly revenue growth is -1.20% - implies potential difficulty sustaining topline expansion and sensitivity to demand cycles.
• Valuation: enterprise value to EBITDA (EV/EBITDA) = 15.38 - suggests a relatively rich valuation versus current earnings, which may compress upside if earnings stagnate or decline.
• Cash flow: operating cash flow (TTM) = CNY 499.39 million - adequate positive cash generation, but susceptible to working-capital swings and operational efficiency changes.
• Capital structure balance: total debt CNY 1.78 billion vs. total equity CNY 3.43 billion - indicates a balanced but non-negligible reliance on debt financing.
• Market risk: stock beta = 0.51 - lower volatility relative to the market, which reduces systematic risk exposure but may limit rapid upside participation in strong rallies.

• Operational risk: negative quarterly revenue growth combined with working-capital variability could pressure margins and cash conversion cycles.
• Refinancing and interest-rate risk: although leverage is moderate, interest-cost increases or tighter credit markets could raise financing costs for CNY 1.78 billion of debt.
• Valuation risk: EV/EBITDA of 15.38 means expectations are priced in; any earnings shortfall could result in share-price re-rating.
• Liquidity and coverage: monitor operating cash flow vs. scheduled debt service and capex - CNY 499.39 million operating cash flow must be weighed against near-term obligations.
• Market-movement risk: low beta (0.51) reduces sensitivity to market rallies but does not protect from idiosyncratic company news or sector downturns.

Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) - Growth Opportunities

• Global vitamin E footprint: ~15% market share, providing scale advantages in a segment forecasted to grow at ~7.5% CAGR from 2023-2030.
• Nutraceutical exposure: participation in a global market projected to reach roughly $650 billion by 2025, supporting premium pricing and margin expansion.
• Recent commercial momentum: nutraceuticals segment delivered ~20% YoY revenue growth as of Q3 2023, driven largely by high-quality vitamin E sales.
• Bio-pesticide expansion target: increase Chinese market share from 8% (2023) to 13% by 2025, with targeted international market entry (Europe, North America) accounting for an additional 5% penetration goal.
• Sustainability and efficiency goals: 30% reduction in carbon emissions per unit by 2024, aligning with customer and regulatory expectations.
• Customer impact: targeted average crop-yield improvements of ~15% for users of its products, estimated to generate CNY 1.2 billion additional revenue for farmers served.

• Commercial strategy: leverage vitamin E scale to cross-sell into nutraceutical channels and use R&D to differentiate formulations for higher-margin end-markets.
• Geographic expansion: phased entry into EU and North American bio-pesticide markets to capture the targeted +5% international penetration and diversify regulatory risk.
• ESG and operational efficiencies: meeting the -30% carbon intensity objective can reduce regulatory and customer risk while improving unit economics.